➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Express Scripts
McKinsey
Baxter
Johnson and Johnson

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for fluocinolone acetonide; hydroquinone; tretinoin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00472966 ↗ Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Completed Galderma Laboratories, L.P. Phase 4 2006-11-01 To determine the effectiveness and safety of sequential therapy with of Tri-Luma® Cream and a series of Glycolic Acid peels in treatment of moderate to severe melasma.
NCT00669071 ↗ Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma Terminated Galderma Laboratories, L.P. Phase 4 2008-01-01 This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period.
NCT00975312 ↗ Solar Lentigines Treatment With the Triple Combination Cream Completed Galderma Laboratories, L.P. Phase 2 2008-08-01 Background - Lentigines are usually the first sign of photoaging and may produce a significant impact on patients' quality of life. - There is no a treatment of choice for this condition. - Solar lentigines and melasma share similar physiopathologic characteristics. - The triple combination (TC) cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) has been effective and safe for the treatment of melasma and other hyperpigmented lesions. Hypothesis * The TC cream will be effective and safe for the treatment of solar lentigines on the back of the hands. Patients and methods - 22 patients with solar lentigines were selected and their right hand or left hand were selected at random to be treated with either TC cream or tretinoin 0.05% cream once daily for up 12 weeks. - Patients were instructed to apply both creams on the whole back of the hand and not only in the lentigines, and to use a broad-spectrum sunscreen (SPF 50+, UVA-PF 28) daily in both hands. - Clinical assessments of Target Lesion Pigmentation, Physician's Global Assessment of Improvement and a Subject's Self-Assessment questionnaire were collected for data analysis at weeks 4, 8, and 12 after starting the treatment and 3 month post-treatment. - Statistical methods: The ordinally scaled efficacy measures underwent rank transformation and were analyzed by analysis of variance to test the null hypothesis of no differences among treatments. We performed Mann-Whitney and Wilcoxon tests and the XLSTAT 2009 software was used.
NCT00975312 ↗ Solar Lentigines Treatment With the Triple Combination Cream Completed Pontificia Universidad Catolica de Chile Phase 2 2008-08-01 Background - Lentigines are usually the first sign of photoaging and may produce a significant impact on patients' quality of life. - There is no a treatment of choice for this condition. - Solar lentigines and melasma share similar physiopathologic characteristics. - The triple combination (TC) cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) has been effective and safe for the treatment of melasma and other hyperpigmented lesions. Hypothesis * The TC cream will be effective and safe for the treatment of solar lentigines on the back of the hands. Patients and methods - 22 patients with solar lentigines were selected and their right hand or left hand were selected at random to be treated with either TC cream or tretinoin 0.05% cream once daily for up 12 weeks. - Patients were instructed to apply both creams on the whole back of the hand and not only in the lentigines, and to use a broad-spectrum sunscreen (SPF 50+, UVA-PF 28) daily in both hands. - Clinical assessments of Target Lesion Pigmentation, Physician's Global Assessment of Improvement and a Subject's Self-Assessment questionnaire were collected for data analysis at weeks 4, 8, and 12 after starting the treatment and 3 month post-treatment. - Statistical methods: The ordinally scaled efficacy measures underwent rank transformation and were analyzed by analysis of variance to test the null hypothesis of no differences among treatments. We performed Mann-Whitney and Wilcoxon tests and the XLSTAT 2009 software was used.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for fluocinolone acetonide; hydroquinone; tretinoin

Condition Name

Condition Name for fluocinolone acetonide; hydroquinone; tretinoin
Intervention Trials
Melasma 2
Lentigo 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for fluocinolone acetonide; hydroquinone; tretinoin
Intervention Trials
Melanosis 2
Lentigo 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for fluocinolone acetonide; hydroquinone; tretinoin

Trials by Country

Trials by Country for fluocinolone acetonide; hydroquinone; tretinoin
Location Trials
United States 3
Chile 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for fluocinolone acetonide; hydroquinone; tretinoin
Location Trials
Tennessee 1
California 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for fluocinolone acetonide; hydroquinone; tretinoin

Clinical Trial Phase

Clinical Trial Phase for fluocinolone acetonide; hydroquinone; tretinoin
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for fluocinolone acetonide; hydroquinone; tretinoin
Clinical Trial Phase Trials
Completed 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for fluocinolone acetonide; hydroquinone; tretinoin

Sponsor Name

Sponsor Name for fluocinolone acetonide; hydroquinone; tretinoin
Sponsor Trials
Galderma Laboratories, L.P. 3
Pontificia Universidad Catolica de Chile 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for fluocinolone acetonide; hydroquinone; tretinoin
Sponsor Trials
Industry 3
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Boehringer Ingelheim
McKinsey
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.